EdgarLookup

O-I Glass, Inc. /DE/ — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that O-I Glass, Inc. /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-2%
Profit Margin
Net income ÷ revenue
-1.4%
Return on Assets
Net income ÷ assets
-1.6%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $6.43B Feb 12, 2026
FY2025 Dec 31, 2024 $6.53B Feb 12, 2026
FY2025 Dec 31, 2023 $7.11B Feb 12, 2026
FY2024 Dec 31, 2022 $6.86B Feb 12, 2025

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.11B Feb 12, 2026
FY2025 Dec 31, 2024 $1.05B Feb 12, 2026
FY2025 Dec 31, 2023 $1.50B Feb 12, 2026
FY2024 Dec 31, 2022 $1.21B Feb 12, 2025
FY2023 Dec 31, 2021 $1.09B Feb 14, 2024
FY2022 Dec 31, 2020 $972.00M Feb 8, 2023
FY2021 Dec 31, 2019 $1.21B Feb 9, 2022
FY2020 Dec 31, 2018 $1.28B Feb 16, 2021
FY2019 Dec 31, 2017 $1.33B Feb 21, 2020
FY2018 Dec 31, 2016 $1.31B Feb 14, 2019

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($129.00M) Feb 12, 2026
FY2025 Dec 31, 2024 ($106.00M) Feb 12, 2026
FY2025 Dec 31, 2023 ($103.00M) Feb 12, 2026
FY2024 Dec 31, 2022 $584.00M Feb 12, 2025
FY2023 Dec 31, 2021 $149.00M Feb 14, 2024
FY2022 Dec 31, 2020 $249.00M Feb 8, 2023
FY2021 Dec 31, 2019 ($400.00M) Feb 9, 2022
FY2020 Dec 31, 2018 $257.00M Feb 16, 2021
FY2019 Dec 31, 2017 $180.00M Feb 21, 2020
FY2018 Dec 31, 2016 $209.00M Feb 14, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $38.00M Feb 12, 2025
FY2024 Dec 31, 2023 $67.00M Feb 12, 2025
FY2024 Dec 31, 2022 $805.00M Feb 12, 2025
FY2023 Dec 31, 2021 $332.00M Feb 14, 2024
FY2022 Dec 31, 2020 $353.00M Feb 8, 2023

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $42.00M Feb 12, 2026
FY2025 Dec 31, 2024 $80.00M Feb 12, 2026
FY2025 Dec 31, 2023 $92.00M Feb 12, 2026
FY2024 Dec 31, 2022 $79.00M Feb 12, 2025
FY2023 Dec 31, 2021 $82.00M Feb 14, 2024
FY2022 Dec 31, 2020 $75.00M Feb 8, 2023
FY2021 Dec 31, 2019 $68.00M Feb 9, 2022
FY2020 Dec 31, 2018 $70.00M Feb 16, 2021
FY2019 Dec 31, 2017 $60.00M Feb 21, 2020
FY2018 Dec 31, 2016 $65.00M Feb 14, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $434.00M Feb 12, 2026
FY2025 Dec 31, 2024 $445.00M Feb 12, 2026
FY2025 Dec 31, 2023 $540.00M Feb 12, 2026
FY2024 Dec 31, 2022 $496.00M Feb 12, 2025
FY2023 Dec 31, 2021 $433.00M Feb 14, 2024
FY2022 Dec 31, 2020 $403.00M Feb 8, 2023
FY2021 Dec 31, 2019 $439.00M Feb 9, 2022
FY2020 Dec 31, 2018 $483.00M Feb 16, 2021
FY2019 Dec 31, 2017 $484.00M Feb 21, 2020
FY2018 Dec 31, 2016 $503.00M Feb 14, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $600.00M Feb 12, 2026
FY2025 Dec 31, 2024 $489.00M Feb 12, 2026
FY2025 Dec 31, 2023 $818.00M Feb 12, 2026
FY2024 Dec 31, 2022 $154.00M Feb 12, 2025
FY2023 Dec 31, 2021 $687.00M Feb 14, 2024
FY2022 Dec 31, 2020 $457.00M Feb 8, 2023
FY2021 Dec 31, 2019 $405.00M Feb 9, 2022
FY2020 Dec 31, 2018 $791.00M Feb 16, 2021
FY2019 Dec 31, 2017 $721.00M Feb 21, 2020
FY2018 Dec 31, 2016 $751.00M Feb 14, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $432.00M Feb 12, 2026
FY2025 Dec 31, 2024 $617.00M Feb 12, 2026
FY2025 Dec 31, 2023 $688.00M Feb 12, 2026
FY2024 Dec 31, 2022 $539.00M Feb 12, 2025
FY2023 Dec 31, 2021 $398.00M Feb 14, 2024
FY2022 Dec 31, 2020 $311.00M Feb 8, 2023
FY2021 Dec 31, 2019 $426.00M Feb 9, 2022
FY2020 Dec 31, 2018 $536.00M Feb 16, 2021
FY2019 Dec 31, 2017 $441.00M Feb 21, 2020
FY2018 Dec 31, 2016 $454.00M Feb 14, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $9.24B Feb 12, 2026
FY2025 Dec 31, 2024 $8.65B Feb 12, 2026
FY2025 Dec 31, 2023 $9.67B Feb 12, 2026
FY2024 Dec 31, 2022 $9.06B Feb 12, 2025
FY2023 Dec 31, 2021 $8.83B Feb 14, 2024
FY2022 Dec 31, 2020 $8.88B Feb 8, 2023
FY2021 Dec 31, 2019 $9.61B Feb 9, 2022
FY2020 Dec 31, 2018 $9.70B Feb 16, 2021
FY2019 Dec 31, 2017 $9.76B Feb 21, 2020
FY2018 Dec 31, 2016 $9.14B Feb 14, 2019

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.29B Feb 12, 2026
FY2025 Dec 31, 2024 $1.08B Feb 12, 2026
FY2024 Dec 31, 2023 $1.61B Feb 12, 2025
FY2023 Dec 31, 2022 $1.42B Feb 14, 2024
FY2022 Dec 31, 2021 $720.00M Feb 8, 2023
FY2021 Dec 31, 2020 $297.00M Feb 9, 2022
FY2020 Dec 31, 2019 $467.00M Feb 16, 2021
FY2019 Dec 31, 2018 $786.00M Feb 21, 2020
FY2018 Dec 31, 2017 $808.00M Feb 14, 2019
FY2017 Dec 31, 2016 $254.00M Feb 14, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.49B Feb 12, 2026
FY2025 Dec 31, 2024 $1.32B Feb 12, 2026
FY2025 Dec 31, 2023 $1.47B Feb 12, 2026
FY2025 Dec 31, 2022 $1.81B Feb 12, 2026
FY2024 Dec 31, 2021 $1.84B Feb 12, 2025
FY2023 Dec 31, 2020 $1.95B Feb 14, 2024
FY2022 Dec 31, 2019 $1.93B Feb 8, 2023
FY2021 Dec 31, 2018 $2.51B Feb 9, 2022
FY2020 Dec 31, 2017 $2.59B Feb 16, 2021
FY2019 Dec 31, 2016 $2.46B Feb 21, 2020

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $548.00M Feb 12, 2026
FY2025 Dec 31, 2024 $676.00M Feb 12, 2026
FY2024 Dec 31, 2023 $782.00M Feb 12, 2025
FY2023 Dec 31, 2022 $885.00M Feb 14, 2024
FY2022 Dec 31, 2021 $301.00M Feb 8, 2023
FY2021 Dec 31, 2020 $152.00M Feb 9, 2022
FY2020 Dec 31, 2019 ($89.00M) Feb 16, 2021
FY2019 Dec 31, 2018 $333.00M Feb 21, 2020
FY2018 Dec 31, 2017 $84.00M Feb 14, 2019
FY2017 Dec 31, 2016 ($96.00M) Feb 14, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $759.00M Feb 12, 2026
FY2025 Dec 31, 2024 $734.00M Feb 12, 2026
FY2024 Dec 31, 2023 $913.00M Feb 12, 2025
FY2023 Dec 31, 2022 $773.00M Feb 14, 2024
FY2022 Dec 31, 2021 $725.00M Feb 8, 2023
FY2021 Dec 31, 2020 $563.00M Feb 9, 2022
FY2020 Dec 31, 2019 $551.00M Feb 16, 2021
FY2019 Dec 31, 2018 $512.00M Feb 21, 2020
FY2018 Dec 31, 2017 $492.00M Feb 14, 2019
FY2017 Dec 31, 2016 $492.00M Feb 14, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2011 Dec 31, 2011 $3.70B Feb 9, 2012
FY2010 Dec 31, 2010 $4.02B Feb 10, 2011
FY2010 Dec 31, 2009 $3.31B Feb 10, 2011

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Feb 12, 2026
FY2025 Dec 31, 2024 0 Feb 12, 2026
FY2025 Dec 31, 2023 0 Feb 12, 2026
FY2024 Dec 31, 2022 3 Feb 12, 2025
FY2023 Dec 31, 2021 0 Feb 14, 2024
FY2022 Dec 31, 2020 1 Feb 8, 2023
FY2021 Dec 31, 2019 (2) Feb 9, 2022
FY2020 Dec 31, 2018 1 Feb 16, 2021
FY2019 Dec 31, 2017 1 Feb 21, 2020
FY2018 Dec 31, 2016 1 Feb 14, 2019

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Feb 12, 2026
FY2025 Dec 31, 2024 0 Feb 12, 2026
FY2025 Dec 31, 2023 0 Feb 12, 2026
FY2024 Dec 31, 2022 3 Feb 12, 2025
FY2023 Dec 31, 2021 0 Feb 14, 2024
FY2022 Dec 31, 2020 1 Feb 8, 2023
FY2021 Dec 31, 2019 (2) Feb 9, 2022
FY2020 Dec 31, 2018 1 Feb 16, 2021
FY2019 Dec 31, 2017 1 Feb 21, 2020
FY2018 Dec 31, 2016 1 Feb 14, 2019

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2009 Dec 31, 2009 179.92M Feb 10, 2010
FY2009 Dec 31, 2008 178.71M Feb 10, 2010

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2022 Dec 31, 2020 $8.00M Feb 8, 2023
FY2021 Dec 31, 2019 $31.00M Feb 9, 2022